- Home
- ADAP
as 03-27-2025 4:00pm EST
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
| Founded: | 2008 | Country: | United Kingdom |
| Employees: | N/A | City: | ABINGDON, OXFORDSHIRE |
| Market Cap: | 71.6M | IPO Year: | 2015 |
| Target Price: | $1.93 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.22 - $1.65 | Next Earning Date: | 03-20-2025 |
| Revenue: | $178,032,000 | Revenue Growth: | 195.34% |
| Revenue Growth (this year): | -77.46% | Revenue Growth (next year): | 56.87% |
Stock Insider Trading Activity of Adaptimmune Therapeutics plc (ADAP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rawcliffe Adrian | ADAP | Chief Executive Officer | Jan 17 '25 | Sell | $0.58 | 30,601 | $17,773.06 | 44,327 | |
| Lunger John | ADAP | Chief Patient Supply Officer | Jan 17 '25 | Sell | $0.58 | 5,584 | $3,243.19 | 7,510 | |
| Norry Elliot | ADAP | Chief Medical Officer | Jan 17 '25 | Sell | $0.58 | 5,584 | $3,243.19 | 7,510 | |
| Bertrand William C JR | ADAP | Chief Operating Officer | Jan 17 '25 | Sell | $0.58 | 5,584 | $3,243.19 | 7,510 | |
| Piccina Cintia | ADAP | Chief Commercial Officer | Jan 15 '25 | Sell | $0.57 | 12,991 | $7,467.23 | 18,421 | |
| Rawcliffe Adrian | ADAP | Chief Executive Officer | Jan 13 '25 | Sell | $0.58 | 59,569 | $34,639.46 | 44,327 | |
| Lunger John | ADAP | Chief Patient Supply Officer | Jan 13 '25 | Sell | $0.58 | 19,542 | $11,360.32 | 7,510 | |
| Norry Elliot | ADAP | Chief Medical Officer | Jan 13 '25 | Sell | $0.58 | 22,195 | $12,920.02 | 7,510 | |
| Bertrand William C JR | ADAP | Chief Operating Officer | Jan 13 '25 | Sell | $0.58 | 19,542 | $11,360.32 | 7,510 |
Latest Adaptimmune Therapeutics plc News
ADAP Breaking Stock News: Dive into ADAP Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
3 days ago
ADAP 4Q24 Earnings Review: EPS Miss on 1x Restructuring/Impairment Costs; Potential Capital Raise Adds Risk to the Story
GuruFocus.com
6 days ago
Earnings To Watch: Adaptimmune Therapeutics PLC (ADAP) Reports Q4 2024 Result
GuruFocus.com
7 days ago
Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ...
Zacks Small Cap Research
8 days ago
ADAP: 4Q24 Business Update: Tecelra Launch Progressing + Incremental Cost Savings; Banker-Led Process to Explore Strategic Options
Newsfile
8 days ago
Adaptimmune Provides Q4 and Full Year 2024 Business Update
FastCompany
10 days ago
From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines
Newsfile
15 days ago
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Simply Wall St.
24 days ago
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are retail investors with 50% stake, while 25% is held by hedge funds
Compare ADAP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADAP Adaptimmune Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.